All In Biotech

Drug Trial Radar · NCT02515097

Safety and Efficacy of IDP-122 in Participants With Plaque Psoriasis

A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 213 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

213

Actual

Start

Nov 5, 2015

Primary completion

Mar 15, 2017

Study completion Mar 15, 2017

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Aug 4, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).

Conditions

  • Plaque Psoriasis

Interventions

  • IDP-122 LotionDrug

    Medicated topical lotion

  • IDP-122 Vehicle LotionDrug

    Vehicle topical lotion with no active ingredient

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment Success at Week 8Time frame: Week 8

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Valeant Site 14

    Santa Ana, California

  • Valeant Site 02

    Boynton Beach, Florida

  • Valeant Site 10

    Clearwater, Florida

  • Valeant Site 1

    Tampa, Florida

  • Valeant Site 07

    Plainfield, Indiana

  • Valeant Site 15

    Olathe, Kansas

  • Valeant Site 08

    Fridley, Minnesota

  • Valeant Site 13

    Omaha, Nebraska

  • Valeant Site 04

    New York, New York

  • Valeant Site 12

    Stony Brook, New York

  • Valeant Site 05

    High Point, North Carolina

  • Valeant Site 11

    Knoxville, Tennessee

  • Valeant Site 03

    Houston, Texas

  • Valeant Site 09

    San Antonio, Texas

  • Valeant Site 06

    West Jordan, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.